Acurx Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

29.01.24	Acurx Pharma Reports Positive Data From Phase 2b Study Of Ibezapolstat In CDI (RTTNews)
17.01.24	Acurx Announces Positive Microbiology And Microbiome Data For Ibezapolstat From Phase 2b Trial (RTTNews)
11.12.23	Acurx Announces Positive Phase 2b Results Showing 100% of Patients Who Had Clinical Cure with Ibezapolstat Also Had Sustained Clinical Cure (PR Newswire)
14.11.23	Acurx Pharmaceuticals, Inc. Reports Third Quarter 2023 Results and Provides Business Update (PR Newswire)
02.11.23	Acurx Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. difficile Infection (PR Newswire)
25.10.23	Acurx Pharmaceuticals to Discuss Third Quarter 2023 Financial Results and Provide Business Update (PR Newswire)
19.10.23	Acurx Announces Ibezapolstat Scientific Posters and Presentations at ClostPath 2023 and IDWeek 2023 Scientific Conferences (PR Newswire)
02.10.23	Acurx Pharma Discontinues Phase 2b Trial For Ibezapolstat To Treat C. Difficile Infection (RTTNews)
02.10.23	Acurx Pharmaceuticals Announces Successful Completion and Early Discontinuation of the Ibezapolstat Phase 2b Trial for Treatment of C. difficile Infection (PR Newswire)
12.09.23	Acurx Announces Presentation and Update of Its pol IIIC R&D Pipeline at the World Antimicrobial Resistance Scientific Congress (PR Newswire)
22.08.23	Acurx Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference September 11-13, 2023 (PR Newswire)
14.08.23	Acurx Pharma's Phase 2b Study Of Ibezapolstat In C. Difficile Infection On Track (RTTNews)
14.08.23	Acurx Pharmaceuticals, Inc. Reports Second Quarter 2023 Results and Provides Business Update (PR Newswire)
24.07.23	Acurx Pharmaceuticals to Discuss Second Quarter 2023 Financial Results and Provide Business Update (PR Newswire)
20.06.23	Acurx Pharmaceuticals to Present at the Emerging Growth Conference on July 12, 2023 (PR Newswire)
15.06.23	Acurx Pharmaceuticals to Participate in the Maxim Group LLC Virtual Healthcare Conference on Tuesday, June 20, 2023 to Thursday, June 22, 2023 at 9 am ET (PR Newswire)
16.05.23	Acurx Pharmaceuticals, Inc. Announces Pricing of $4.0 Million Registered Direct Offering (PR Newswire)
12.05.23	Acurx Pharmaceuticals, Inc. Reports First Quarter 2023 Results and Provides Business Update (PR Newswire)
05.05.23	Acurx Pharmaceuticals to Discuss First Quarter 2023 Financial Results and Provide Business Update (PR Newswire)
19.04.23	Acurx Announces Ibezapolstat Scientific Poster and Update on its Pol IIIC Pipeline Presented at ECCMID 2023 Scientific Conference (PR Newswire)
11.04.23	FDA Accepts Interim Analysis Plan for Ongoing Phase 2b Ibezapolstat Clinical Trial and Acurx Announces Presentations at ECCMID 2023 Scientific Conference (PR Newswire)
16.03.23	Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2022 Results and Provides Business Update (PR Newswire)
06.03.23	Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update (PR Newswire)
16.01.23	Acurx Pharmaceuticals to Present at the Emerging Growth Conference on January 25, 2023 (PR Newswire)
14.11.22	Acurx Pharmaceuticals, Inc. Reports Third Quarter 2022 Results and Provides Business Update (PR Newswire)
01.11.22	Acurx Pharmaceuticals, Inc. to Discuss 2022 Third Quarter Financial Results on November 14, 2022 Conference Call and Provide Business Update (PR Newswire)
26.10.22	Acurx Announces Scientific Oral and Poster Presented at IDWeek 2022 (PR Newswire)
17.10.22	Acurx Announces Scientific Oral and Poster Presentations at IDWeek (PR Newswire)
15.08.22	Acurx Pharmaceuticals, Inc. Reports Second Quarter 2022 Results and Provides Business Update (PR Newswire)
04.08.22	Acurx Pharmaceuticals, Inc. to Discuss 2022 Second Quarter Financial Results on August 16, 2022 Conference Call and Provide Business Update (PR Newswire)
02.08.22	Acurx Announces New Data Presentations from Ongoing Ph2 Clinical Trial Program of Ibezapolstat for CDI at the 16th Biennial Congress of the Anaerobe Society of America (PR Newswire)
25.07.22	Acurx Pharmaceuticals, Inc. Announces $4.225 Million Registered Direct Offering (PR Newswire)
11.05.22	Acurx Pharmaceuticals, Inc. Reports First Quarter 2022 Results and Provides Business Update (PR Newswire)
29.04.22	Acurx Pharmaceuticals, Inc. to Discuss 2022 First Quarter Financial Results on May 11, 2022 Conference Call and Provide Business Update (PR Newswire)
17.03.22	Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update (PR Newswire)
16.03.22	Acurx Pharmaceuticals to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28-30, 2022 from 9:00 a.m. - 5:00 p.m. EDT (PR Newswire)
07.03.22	Acurx Pharmaceuticals to Discuss Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update (PR Newswire)
07.02.22	Acurx Announces Publication of Positive Phase 2a Clinical Trial Results of Ibezapolstat for CDI in Clinical Infectious Diseases (PR Newswire)
06.12.21	Acurx Announces First Patient Enrolled in Phase 2b Clinical Trial of its Lead Antibiotic for Treatment of Clostridioides difficile Infection (CDI) (PR Newswire)
13.11.21	Acurx Pharmaceuticals, Inc. Reports Third Quarter 2021 Results and Provides Business Update (PR Newswire)
08.11.21	Acurx Announces New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for CDI at the 9th International C. diff. Conference (PR Newswire)
01.11.21	Acurx Announces New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for CDI at the 9th International C. diff. Conference (PR Newswire)
27.10.21	Acurx Pharmaceuticals to Discuss 2021 Third Quarter Financial Results on November 15, 2021 Conference Call and Provide Business Update (PR Newswire)
04.10.21	Acurx Presents Positive Ibezapolstat Microbiome Data from Its Phase 2a Trial at IDWeek (PR Newswire)
30.09.21	Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2021 (PR Newswire)
29.09.21	Acurx Pharmaceuticals to Participate in the A.G.P. Biotech and Specialty Pharma Conference October 13, 2021 (PR Newswire)
27.09.21	Acurx Announces New Microbiome Data from Its Phase 2a Clinical Trial of Ibezapolstat for CDI in a Scientific Poster Presentation at IDWeek 2021 Conference (PR Newswire)
02.09.21	Acurx Pharmaceuticals to Join the Russell Microcap Index® (PR Newswire)
31.08.21	Acurx Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021 (PR Newswire)
16.08.21	Acurx Pharmaceuticals, Inc. Reports Second Quarter 2021 Results and Provides Business Update (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Acurx Pharmaceuticals Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten